Vandetanib is an anticancer chemotherapeutic and anti-angiogenic compound that acts as an ATP-competitive inhibitor of RET, EGFR, and VEGFR2. In a cellular model of medullary thyroid carcinoma, vandetanib inhibits phosphorylation of RET, Shc, and MAPKs, inhibiting cell proliferation. In glioblastoma cells, vandetanib induces autophagy and apoptosis, and in a similar in vivo model, prevents tumor growth. In separate animal models, vandetanib’s inhibition of VEGFR2 decreases tumor microvessel density and tumor cell proliferation. Vandetanib also induces hypertension and prolongs the cardiac QT interval in clinical settings.